🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT05711992
Recruiting

Rare Embryonal Tumors of the Central Nervous System: International Registry

NCT05711992 · tracked via the Priya Life Science India tracker
Sponsor
Immune Oncology Research Institute
Phase
Started
2023-02-01
Last updated
2025-05-08

Condition(s) studied

Embryonal Tumor

Study summary

Central nervous system (CNS) tumors are the most common solid malignancies among children. Although some types of CNS tumors like medulloblastomas and low-grade gliomas are widespread and well-studied, there is a huge number of rare diseases that need further research. This international registry aims to establish a large multicenter database of pediatric and young adult patients with rare embryonal tumors of the central nervous system and describe the clinical presentations, diagnostics, treatment regimens, and outcomes. Embryonal tumors with multilayered rosettes (ETMR), FOXR2-activated CNS neuroblastoma, cribriform neuroepithelial tumor, and CNS tumor with BCOR internal tandem duplication are extremely rare embryonal tumors some of which were first described in the last edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System. Objectives of the registry are 1) to evaluate prognostic factors, 2) to identify diagnostic and treatment gaps, 3) to investigate the characteristics and outcome of the disease with different treatment regimens, and 4) to generate data-based prospective diagnostic and treatment recommendations.

Eligibility

Sex
ALL
Min age
1 Day
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with rare embryonal tumors of CNS since 01.01.2010: * ETMR (including embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma (EBL) and medulloepithelioma (MEPL) which were previously classified as CNS-PNETs) * FOXR2-activated CNS neuroblastoma * cribriform neuroepithelial tumor * CNS tumor with BCOR internal tandem duplication * all patients diagnosed with neuroblastoma and ganglioneuroblastoma with no molecular genetic tests available * Patients ≤ 25 years of age * Signed informed consent form for prospective patients ≥ 18 years of age * Signed parental permission and child assent forms for prospective patients \< 18 years of age Exclusion Criteria: • CNS metastases of extracranial embryonal tumors

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Hematology Center named after prof. R. Yeolyan Yerevan Armenia Recruiting
Children's Hospital of Eastern Ontario (CHEO) Ottawa Canada Recruiting
Semmelweis University Budapest Hungary Recruiting
National Cancer Institute, All India Institutes of Medical Sciences New Delhi India Recruiting
Oncology Department of Golestan hospital Tehran Iran Recruiting
IRCCS Istituto Ospedale Pediatrico Bambino Gesù Rome Italy Recruiting
Hospital Civil de Guadalajara "Dr. Juan I. Menchaca" Guadalajara Mexico Recruiting
Centro Médico ABC Mexico City Mexico Recruiting
Hospital Nacional Alberto Sabogal Sologuren - EsSalud Bellavista Peru Recruiting
Hospital Nacional Edgardo Rebagliati Martins Lima Peru Recruiting
China Medical University Children's Hospital Taichung Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05711992 on ClinicalTrials.gov ↗ ← All trials in India